Results 151 to 160 of about 777,778 (283)

ICU‐EEG Pattern Detection by a Convolutional Neural Network

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Patients in the intensive care unit (ICU) often require continuous EEG (cEEG) monitoring due to the high risk of seizures and rhythmic and periodic patterns (RPPs). However, interpreting cEEG in real time is resource‐intensive and heavily relies on specialized expertise, which is not always available.
Giulio Degano   +5 more
wiley   +1 more source

Animal Models of Neurological Disease [PDF]

open access: yesJournal of Neurology, Neurosurgery & Psychiatry, 1982
openaire   +2 more sources

Long‐Term Evaluation of Givinostat in Duchenne Muscular Dystrophy, and Natural History Comparisons

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives This ongoing, open‐label extension study is evaluating the long‐term safety, tolerability, and efficacy of givinostat, a Class I and II histone deacetylase inhibitor, in patients with Duchenne muscular dystrophy (DMD). Methods The recruited patients completed one of two prior clinical studies (one Phase 2 and one Phase 3 [EPIDYS ...
Craig M. McDonald   +74 more
wiley   +1 more source

Commentary on “The Impact of Diabetes and Metabolic Syndrome Burden on Pain, Neuropathy Severity and Fiber Type”

open access: yes
Annals of Clinical and Translational Neurology, EarlyView.
Majid Khalilizad   +4 more
wiley   +1 more source

SYHA1813, A VEGFR and CSF1R Inhibitor, in Patients With Recurrent High‐Grade Gliomas: A Multicenter, Open‐Label Phase I Study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Recurrent high‐grade gliomas have a poor prognosis and limited therapeutic options. This study aimed to evaluate the safety and efficacy of SYHA1813, a dual inhibitor of VEGFR and CSF1R, in patients with recurrent high‐grade gliomas.
Zhuang Kang   +16 more
wiley   +1 more source

Mouse models of neurological disorders

open access: yesBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2010
openaire   +2 more sources

Protein production is an early biomarker for RNA‐targeted therapies [PDF]

open access: yes, 2018
Alex, Jacob   +10 more
core   +2 more sources

Durability of Response to B‐Cell Maturation Antigen‐Directed mRNA Cell Therapy in Myasthenia Gravis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective We report the 12‐month follow‐up outcomes from a Phase 2 clinical trial (NCT04146051) evaluating Descartes‐08, a BCMA‐directed RNA chimeric antigen receptor T‐cell (rCAR‐T) therapy for refractory generalized myasthenia gravis (MG).
Nizar Chahin   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy